Waldenström Macroglobulinemia (WM): Treatment & Prognosis
Core treatment principles
Waldenström Macroglobulinemia
WM:
- ยัง “ไม่ curable”
- แต่เป็น indolent disease ในผู้ป่วยส่วนใหญ่
- median
survival ปัจจุบัน >10 ปี
Goals:
- control
symptoms
- prevent
end-organ damage
- preserve
quality of life
- minimize
toxicity
Important concept
“Treat symptoms — not numbers”
WM:
ไม่รักษาเพียงเพราะ IgM สูง
ถ้ายัง:
- asymptomatic
- ไม่มี organ damage
- ไม่มี cytopenia significant
→
observe ได้
Pretreatment evaluation
Important history/physical
ต้องหา:
Hyperviscosity
- epistaxis
- blurred
vision
- headache
- dizziness
Neuropathy
- distal
sensory neuropathy
- anti-MAG
related
Cryoglobulinemia
- Raynaud
- purpura
- ischemia
Cold agglutinin disease
- acrocyanosis
- hemolysis
AL amyloidosis
- nephrotic
syndrome
- cardiomyopathy
- macroglossia
Bing-Neel syndrome
(CNS involvement)
- seizure
- AMS
- cranial
neuropathy
Baseline investigations
Labs
|
Investigation |
Purpose |
|
CBC |
cytopenia |
|
CMP |
kidney/liver |
|
LDH |
prognosis |
|
SPEP/immunofixation |
M protein |
|
Quantitative Ig |
IgM burden |
|
Beta-2 microglobulin |
prognosis |
|
Serum FLC |
tumor burden |
Additional tests
|
Test |
Indication |
|
Serum viscosity |
hyperviscosity suspicion |
|
Coombs |
cold agglutinin |
|
PT/aPTT/VWD studies |
bleeding |
|
HBV/HCV/HIV |
before therapy |
Bone marrow
Need:
- morphology
- immunophenotype
- MYD88
mutation
- ±
CXCR4 mutation
Imaging
CT chest/abdomen/pelvis:
- lymphadenopathy
- organ
involvement
PET/CT:
- suspected
aggressive transformation
Asymptomatic WM
“Smoldering WM”
Important principle
NO treatment initially
เพราะ:
- survival
benefit ไม่มี
- treatment
toxicity significant
Follow-up
Typical:
- CBC
- IgM
level
ทุก: - 3–6 เดือน
Risk factors for progression
Higher risk:
- IgM ≥4500
- marrow
infiltration ≥70%
- B2M ≥4
- albumin
≤3.5
- MYD88
wild-type
Median time to progression
|
Risk |
Median TTP |
|
Low |
9.3 yr |
|
Intermediate |
4.8 yr |
|
High |
1.8 yr |
Indications for treatment
Treat only if symptomatic disease
1. Constitutional symptoms
- fever
- night
sweats
- weight
loss
- fatigue
2. Cytopenias
Typical thresholds:
- Hb ≤10
- platelet
<100k
3. Symptomatic organ infiltration
- bulky
LAD
- hepatosplenomegaly
- tissue
infiltration
4. End-organ damage
- hyperviscosity
- neuropathy
- amyloidosis
- cryoglobulinemia
- nephropathy
- pleural
effusion
Hyperviscosity syndrome
Medical emergency
Symptoms
- headache
- blurry
vision
- mucosal
bleeding
- dizziness
- retinal
hemorrhage
- coma/stupor
Treatment
Immediate plasmapheresis
สำคัญ:
อย่ารอ viscosity result
Treat from clinical picture
Why plasmapheresis works well in WM
IgM mostly intravascular
→ remove
rapidly
One session:
- ↓ IgM ~30–50%
Important pearl
Avoid RBC transfusion before plasmapheresis
เพราะ:
- เพิ่ม viscosity
- worsen
HF/hyperviscosity
Important limitation
Plasmapheresis:
ไม่รักษา malignant clone
จึงต้องตามด้วย:
- systemic
therapy
Rituximab-induced IgM flare
สำคัญมาก
Mechanism
หลัง rituximab:
IgM อาจ “สูงขึ้นชั่วคราว”
→
worsen:
- hyperviscosity
- neuropathy
- cryoglobulinemia
High-risk group
Especially:
- IgM
>4000 mg/dL
Prevention strategies
- prophylactic
plasmapheresis
หรือ - withhold
rituximab first cycle
Initial therapy
General principles
เลือก regimen ตาม:
- age
- frailty
- symptoms
- tumor
burden
- comorbidities
- patient
preference
Main frontline options
|
Regimen |
Typical use |
|
BR |
standard preferred |
|
BTK inhibitor |
elderly/frail |
|
DRC |
lower disease burden |
|
BDR |
usually relapse |
Bendamustine + Rituximab (BR)
Preferred first-line for most symptomatic patients
Advantages
- highly
effective
- time-limited
- good
tolerability
Regimen
4–6 cycles
Response
ORR >90%
PFS:
~70 months ในบาง study
Toxicities
- myelosuppression
- infection
- hypogammaglobulinemia
Long-term:
- MDS/AML
risk
BTK inhibitors
Major modern therapy
Drugs
|
Drug |
Status |
|
Ibrutinib |
approved |
|
Zanubrutinib |
preferred BTKi |
|
Acalabrutinib |
active but not officially
approved |
Mechanism
Block:
Bruton tyrosine kinase (BTK)
important downstream MYD88 signaling
Zanubrutinib
Current preferred BTKi
Advantages over ibrutinib
Less:
- atrial
fibrillation
- HTN
- diarrhea
- muscle
cramps
Toxicities
- bleeding
- infection
- cytopenia
- arrhythmia
Important pearl
Hold BTKi:
3–7 days pre/post surgery
เพราะ bleeding risk
Ibrutinib
Highly effective
BUT:
- atrial
fibrillation
- HTN
- bleeding
มากกว่า zanubrutinib
Important biologic pearl
Best response:
MYD88 mutated + CXCR4 wild-type
DRC regimen
Dexamethasone + Rituximab + Cyclophosphamide
Characteristics
- less
intensive
- lower
toxicity
- slower
response
Good for:
- lower
disease burden
- frailer
patients
Bortezomib-based therapy (BDR)
Effective but:
- neurotoxicity
significant
Usually reserved:
- relapse
setting
Important pearl
Weekly SC bortezomib:
→ lower neuropathy risk
Role of single-agent rituximab
Generally:
NOT preferred
Because:
- weaker
efficacy
- IgM
flare common
Possible exceptions:
- isolated
neuropathy
- isolated
hemolysis
Follow-up & response assessment
ใช้:
IWWM response criteria
Response categories
|
Response |
Definition |
|
CR |
no IgM + marrow cleared |
|
VGPR |
≥90% IgM reduction |
|
PR |
≥50% reduction |
|
MR |
≥25% reduction |
|
SD |
<25% change |
|
PD |
≥25% increase |
Important pearl
IgM fluctuation:
≠
always progression
Especially after:
- rituximab
- BTKi
interruption
Monitoring after BR
Typical:
- q3mo
first year
- then
q6mo
No routine imaging in asymptomatic patients
Histologic transformation
Rare but important
Transformation →
aggressive lymphoma
Clues
- rapid
LAD growth
- ↑ LDH
- declining
performance
- aggressive
symptoms
Need:
biopsy confirmation
Prognosis poor
Relapsed / refractory WM
Treatment depends on:
- prior
therapy
- time
to relapse
- patient
fitness
If relapse >3 years after chemo
Often:
- repeat
prior regimen
If relapse <3 years
Usually:
- BTK
inhibitor preferred
If progression on BTKi
Options:
- chemoimmunotherapy
- venetoclax
- pirtobrutinib
Venetoclax
Promising in relapsed WM
ORR ~84%
Main toxicity:
- neutropenia
- tumor
lysis
Important warning
BTKi + venetoclax combination
currently NOT recommended outside trial
Because:
- ventricular
arrhythmia deaths reported
Stem cell transplantation
Rarely used now
Reserved for:
- heavily
relapsed
- fit
patients
Usually:
- autologous
HCT
Prognosis
Modern therapy:
median OS >10 years
MSS-WM scoring
Uses:
- age
- albumin
- LDH
Poor prognostic factors
- older
age
- low
albumin
- high
LDH
- high
B2M
Important prognostic concept
WM:
heterogeneous disease มาก
บางราย:
- indolent
>10–15 ปี
บางราย:
- aggressive
progression
High-yield take-home points
- Treat
symptoms, not IgM level alone
- Asymptomatic
WM → observe
- Hyperviscosity
= emergency →
plasmapheresis immediately
- Rituximab
may cause IgM flare
- BR =
preferred frontline regimen for many patients
- Zanubrutinib
= preferred BTKi
- MYD88
mutated + CXCR4 WT →
best BTKi response
